APA (7th ed.) Citation

Nakayama, T., Nagai, S., Hattori, M., Yoshinami, T., Masuda, H., Okamura, T., . . . Masuda, N. (2024). 359P Overall survival of palbociclib (PAL) + endocrine therapy (ET) in Japanese patients with hormone receptor-positive (HR+)/ human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) in the 1st line (1L) or 2nd line (2L) setting: A multicenter observational study. Annals of Oncology, 35, S368. https://doi.org/10.1016/j.annonc.2024.08.307

Chicago Style (17th ed.) Citation

Nakayama, T., et al. "359P Overall Survival of Palbociclib (PAL) + Endocrine Therapy (ET) in Japanese Patients with Hormone Receptor-positive (HR+)/ Human Epidermal Growth Factor Receptor 2-negative (HER2-) Advanced Breast Cancer (ABC) in the 1st Line (1L) or 2nd Line (2L) Setting: A Multicenter Observational Study." Annals of Oncology 35 (2024): S368. https://doi.org/10.1016/j.annonc.2024.08.307.

MLA (9th ed.) Citation

Nakayama, T., et al. "359P Overall Survival of Palbociclib (PAL) + Endocrine Therapy (ET) in Japanese Patients with Hormone Receptor-positive (HR+)/ Human Epidermal Growth Factor Receptor 2-negative (HER2-) Advanced Breast Cancer (ABC) in the 1st Line (1L) or 2nd Line (2L) Setting: A Multicenter Observational Study." Annals of Oncology, vol. 35, 2024, p. S368, https://doi.org/10.1016/j.annonc.2024.08.307.